1. Scrip

12 Key Oncology Drug Launches Expected In 2022 – Hematological Malignancies

 
• By Alexandra Shimmings

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.    

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
• Source: Shutterstock

The Paris-headquartered ERYTECH Pharma S.A. is looking to submit eryaspase to the US Food and Drug Administration in the fourth quarter for hypersensitive acute lymphoblastic leukemia (ALL). This represents a turnaround for the company which had originally filed the product for ALL in the EU before pulling the submission three years ago after deciding that solid tumors, particularly pancreatic cancer, represented the best way forward for the compound. (Also see "Erytech Pulls Graspa ALL Filing To Focus On Pancreatic Cancer" - Scrip, 25 June, 2018.)

Indeed, progress in pancreatic cancer is still on track, and this indication remains the primary focus for the product

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.